In a Phase 1 trial in individuals with obesity, targeted release of glucose with APH-012 induced therapeutically relevant release of a broad spectrum of enteric hormones, including glucagon-like-peptide 1 (GLP-1), peptide tyrosine-tyrosine (PYY), glicentin and oxyntomodulin (OXM) among others.
This effect has not previously been achieved with any other drug-based therapy, as incretin-based therapies only partially correct the endocrine deficiency and induce unphysiological serum concentration peaks of hormones that lead to side effects that limit long-term use [i].
The levels of hormones released by APH-012 were comparable to those measured after ROUX-Y Gastric Bypass surgery (RYGB). RYGB is the only treatment solution at present that addresses the underlying condition of obesity but with massive side effects, that negatively impact quality of life, well-being and prognosis.
Treatment with APH-012 did not induce any adverse events that were different from those in the placebo group, and as such, it has the potential to mimic the metabolic effects of bypass surgery without adverse effects.